Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: BMS | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: BMS

Revenues up 6% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BMS

4Q Revenues: $4.4 billion (+6%)

4Q Earnings: $735.0 million (-20%)

YTD Revenues: $16.4 billion (-7%)

YTD Earnings: $2.6 billion (+3%)

Comments: U.S. revenues increased 1% to $2.3 billion in the quarter and international revenues increased 11% to $2.2 billion. Yervoy sales grew 23% to $260 million. Onglyza/Kombiglyze sales were $224 million, up 13%. Sprycel sales grew 30% to $365 million, and Orencia sales were up 22% to $397 million. Abilify sales were down 22% to $635 million, due to loss of patent exclusivity. R&D expenses were down 12% to $957 million. In the quarter, the company announced the sale of its diabetes business as part of an effort to evolve its BioPharma strategy to a specialty care model.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters